Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195635 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
A Phase 1 study of Drug Interactions, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02195635: Completed Phase 1 study of Drug Interactions, sponsored by Lexicon Pharmaceuticals.
NCT02195635 is a Phase 1 study of Drug Interactions that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 24 participants, below the 726-participant average among 6 other Drug Interactions trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02195635, a Phase 1 study of Drug Interactions, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effect of octreotide acetate injections (200 µg 3 times daily \[tid\]) on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single-dose telotristat etiprate in healthy male and female subjects
Conditions Studied
Interventions
- DRUG Telotristat etiprate
- DRUG Octreotide acetate
Study Locations (1)
Florida
- Lexicon Investigational Site - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-07 |
| Phase | Phase 1 |
What the finished NCT02195635 record still lists
NCT02195635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 726-participant average among 6 other Drug Interactions trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Drug Interactions appearing as the primary indexed condition, and to 2 interventions - of which Telotristat etiprate is the first listed.
NCT02195635 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02195635 about?
NCT02195635 is a clinical study titled "Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects". To evaluate the effect of octreotide acetate injections (200 µg 3 times daily \[tid\]) on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single-dose telotristat etiprate in healthy male and female subjects
What is the current status of trial NCT02195635?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-07.
What conditions does trial NCT02195635 study?
This clinical trial studies the following conditions: Drug Interactions.
What interventions are being tested in trial NCT02195635?
The interventions under investigation include: Telotristat etiprate (DRUG), Octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT02195635?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02195635 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Interactions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Opioid Drug Interaction Study
RECRUITING · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
COMPLETED · Phase 1
-
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
RECRUITING · Phase 4
-
Shared Decision for Drug Interactions in Oral Anticoagulation
RECRUITING · NA
-
Emergency Department (ED) Drug Interaction in Emergency Department Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia